10-Q: Quarterly report
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on May 23
HOUSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW)) is pleased to invite investors to a webinar on May 23, 2024, at 4:15 p.m. ET. The exclusive event,
Nexalin Technology Regains Compliance With Nasdaq Continued Listing Requirements
HOUSTON, TEXAS, April 25, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW)) announced that the Company received notice from The Nasdaq Stock Market ("Nasdaq") on April
Nexalin Technology Accelerates Manufacturing of Its HALO Clarity Following Successful Usability, Feasibility, and Electrical Testing
Mark White, CEO of Nexalin Technology, stated, "I am thrilled to report that the HALOClarity passed a series of rigorous tests, validating our manufacturing process and illustrating that our device meets the highest product standards.
Nexalin Technology Awarded Key Patent Related to Its Gen-3 HALO Clarity, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No. 17/337,653 relating to the Company's non-invasive, frequency-based deep brain stimulation device.
Nexalin Technology Unveils Positive Results of Clinical Study for Gen-2 TACS Device
Nexalin Technology Full Year 2023 Earnings: US$0.63 Loss per Share (Vs US$0.30 Loss in FY 2022)
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin's Technology
HOUSTON, TEXAS, March 14, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW)) today announced that it has commenced sales of its second generation (Gen-2), 15 milliamp
Nexalin Technology Announces Poster Presentation at "State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment"
Event hosted by the U.S. Army Medical Research and Development Command's (USAMRDC) Combat Casualty Care Research Program (CCCRP) Neurotrauma Portfolio and the Biomedical Advanced Research and Development Authority
Nexalin Technology Announces Positive Results From Clinical Study of Its Gen-2 TACS Device for Treating Adult Patients With Chronic Insomnia
Clinical study demonstrated clinically meaningful and statistically significant improvements in key sleep parameters, compared to adult patients treated with placeboData published in Journal of Psychiatric
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
HOUSTON, TEXAS, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW)) today announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device,
Nexalin Technology Awarded Key Patent Related to Its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
HOUSTON, TX, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW)) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S.
Nexalin Technology Unveils Next-Generation HALO Clarity
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of Its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms
HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW)) today provided an update on the growing body of clinical data supporting the potential therapeutic
Nexalin's CEO Mark White to Be Interviewed Live on "The Big Biz Show" Today at 3PM Eastern Time
HOUSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL; NXLIW) today announced that its Chief Executive Officer, Mark White, will be participat
Nexalin Technology Announces Abstract Accepted For Presentation At 2023 Military Health System Research Symposium Validating The Potential Of Its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device For The Treatment Of Mild Traumatic Brain Injury
Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW) today announced that Company's abstract, titled: "MEG Source Imaging Reveals Neuronal Changes in Combat-Related Mild Traumatic Brain Injury after Transcranial Electrical Stimulation using Nexalin," has been accepted for a poster presentation at the upcoming 2023 Military Health System Research Symposium (MHSRS) being held on August 14-17, 2023 at the Gaylord Palms Resort and Convention Center, Kissimmee, Florida, USA.
Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin's TACS Devices in the Asia Pacific Region
HOUSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW)) today announced it has formalized a joint venture arrangement ("JV") with Wider Come Limited
No Data